# Michael A. Postow

Source: https://onco.cc/people/michael-postow/  
OnCo record `michael-postow` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects.

## Summary

Michael Postow led CheckMate 069, the randomised phase 2 trial that first showed nivolumab plus ipilimumab dramatically improves response rates over ipilimumab alone in melanoma and set up CheckMate 067. He wrote the widely cited NEJM review of immune-related adverse events and leads trials of adaptive dosing and treatment discontinuation. He chairs the melanoma service at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; immunotherapy; toxicity
- Role: Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Melanoma; Immunotherapy; Immune-related adverse events; Treatment duration

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [CheckMate 067](https://onco.cc/trials/checkmate-067/)
- key papers: [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/)

---
JSON: https://onco.cc/api/v1/entities/michael-postow.json